MIAMI--(BUSINESS WIRE)--Summit Therapeutics Inc. (NASDAQ: SMMT) (“Summit,” “we,” or the “Company”) today announced topline results from the Phase III clinical trial, HARMONi, the first global Phase ...
Neoadjuvant therapy (NT) in patients with melanoma is associated with promising survival benefits, favorable complete response (CR), and an acceptable safety profile, according to systematic review ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback